Cipla shares broke out above ₹1,580–₹1,590 on strong volumes, with technical indicators signaling further gains.

The Nifty Pharma Index gained more than 1% amid a weak Indian stock market on a day when the benchmark Nifty 50 Index dipped ...

Nomura’s June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Zydus posting strong ...

India's Cipla has signed a deal with Eli Lilly to sell and distribute two of the U.S. drugmaker's best-selling diabetes treatments in the country, the companies said in a joint statement on Monday.

According to Elara Capital’s Domestic Liquidity Tracker, the changes in pharma and tech were led by HDFC MF, ICICI Prudential MF, and SBI Mutual Fund.

Zee Business analysts Ansh Jogendra Bhilwar and Pooja Tripathi have shared a number of calls for trading and investing today, ...

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by ...

The market may continue to consolidate with a negative bias in the upcoming sessions. Below are some short-term trading ideas to consider.

A malaria drug made by India's Cipla has been pre-qualified by the World Health Organization (WHO), an important step towards its roll-out across Asia, where millions of people are infected with ...

As the U.S. gears up to impose a 25% tariff on Indian imports starting August 1, India’s pharmaceutical industry is on alert.